646 related articles for article (PubMed ID: 8044941)
1. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
Thadani U; Ezekowitz M; Fenney L; Chiang YK
Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
[TBL] [Abstract][Full Text] [Related]
2. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris.
Thadani U; Zellner SR; Glasser S; Bittar N; Montoro R; Miller AB; Chaitman B; Schulman P; Stahl A; DiBianco R
Circulation; 1991 Dec; 84(6):2398-408. PubMed ID: 1959195
[TBL] [Abstract][Full Text] [Related]
4. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
Chaitman BR
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group.
Pepine CJ; Wolff AA
Am J Cardiol; 1999 Jul; 84(1):46-50. PubMed ID: 10404850
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
Rousseau MF; Pouleur H; Cocco G; Wolff AA
Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
[TBL] [Abstract][Full Text] [Related]
9. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.
Cocco G; Rousseau MF; Bouvy T; Cheron P; Williams G; Detry JM; Pouleur H
J Cardiovasc Pharmacol; 1992 Jul; 20(1):131-8. PubMed ID: 1383622
[TBL] [Abstract][Full Text] [Related]
10. Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris.
Alpert JS; Bakx AL; Braun S; Frishman WH; Schneeweiss A; Tzivoni D; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):20C-26C. PubMed ID: 9286850
[TBL] [Abstract][Full Text] [Related]
11. Duration of effects of isradipine during twice daily therapy in angina pectoris.
Thadani U; Chrysant S; Gorwit J; Giles T; Archer S; Iteld B; Singh S; Copen D; Wakeford C; Hobbs S
Cardiovasc Drugs Ther; 1994 Apr; 8(2):199-210. PubMed ID: 7918132
[TBL] [Abstract][Full Text] [Related]
12. Discordance between effects of anti-ischemic therapy on ambulatory ischemia, exercise performance and anginal symptoms in patients with stable angina pectoris. The Angina and Silent Ischemia Study Group (ASIS).
Borzak S; Fenton T; Glasser SP; Shook TL; MacCallum G; Young PM; Stone PH
J Am Coll Cardiol; 1993 Jun; 21(7):1605-11. PubMed ID: 8496526
[TBL] [Abstract][Full Text] [Related]
13. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Stone PH; Gratsiansky NA; Blokhin A; Huang IZ; Meng L;
J Am Coll Cardiol; 2006 Aug; 48(3):566-75. PubMed ID: 16875985
[TBL] [Abstract][Full Text] [Related]
14. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate.
Thadani U; Maranda CR; Amsterdam E; Spaccavento L; Friedman RG; Chernoff R; Zellner S; Gorwit J; Hinderaker PH
Ann Intern Med; 1994 Mar; 120(5):353-9. PubMed ID: 8093132
[TBL] [Abstract][Full Text] [Related]
15. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial.
Sendón JL; Lee S; Cheng ML; Ben-Yehuda O;
Eur J Prev Cardiol; 2012 Oct; 19(5):952-9. PubMed ID: 22689417
[TBL] [Abstract][Full Text] [Related]
16. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study.
Sellier P; Broustet JP
Am J Cardiovasc Drugs; 2003; 3(5):361-9. PubMed ID: 14728070
[TBL] [Abstract][Full Text] [Related]
17. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
[TBL] [Abstract][Full Text] [Related]
18. Effect of dipyridamole therapy on myocardial ischemia in patients with stable angina pectoris receiving concurrent anti-ischemic therapy.
Barbour MM; Garber CE; Agarwal KC; Malhotra R; Heller GV
Am J Cardiol; 1992 Feb; 69(5):449-52. PubMed ID: 1736604
[TBL] [Abstract][Full Text] [Related]
19. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
Ruzyllo W; Tendera M; Ford I; Fox KM
Drugs; 2007; 67(3):393-405. PubMed ID: 17335297
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium.
Jain D; Dasgupta P; Hughes LO; Lahiri A; Raftery EB
Eur J Clin Pharmacol; 1990; 38(2):111-4. PubMed ID: 2110906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
